FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT in Adult and Paediatric Patients with AML or MDS By Ogkologos - March 13, 2025 810 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Darolutamide August 7, 2025 After Spine Tumor, Teacher Goes On Mission To Serenade Hospital Patients... June 24, 2019 Haematologic Toxicity Not Increased with Immunochemotherapy Combinations Over Chemotherapy Treatment for... December 9, 2020 No Clinically Meaningful Difference in Survival Between Nivolumab Plus Ipilimumab and... September 20, 2023 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Olaparib to Patients with... Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line... Scientists Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers... ETV6 Protein Could Be an Important Target for Ewing Sarcoma Treatment
